Yuichi Okumura InnoJin, Inc., Code E (Employment), Johnson & Johnson., FUKOKU Co., Ltd, Code F (Financial Support), InnoJin, Inc., Code P (Patent);
Masakazu Hirota InnoJin, Inc., Code E (Employment);
Akie Midorikawa-Inomata InnoJin, Inc., Code E (Employment);
Ken Nagino InnoJin, Inc., Code E (Employment);
takashi negishi None;
Eiji Ogawa InnoJin, Inc., Code E (Employment);
Shintaro Nakao Kowa Company. Ltd., Mitsubishi Tanabe Pharma Corporation, Alcon Japan, Ltd., Santen Pharmaceutical Co., Ltd., Machida Endoscope Co., Ltd., Wakamoto Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Senju Pharmaceutical Co., Ltd. Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Hoya Corporation, and Novartis Pharma K.K., Code F (Financial Support);
Takenori Inomata Santen Pharmaceutical Co., Ltd., Code C (Consultant/Contractor), InnoJin, Inc., Code E (Employment), Novartis Pharma KK, Santen Pharmaceutical Co., Ltd., Lion Corporation, SEED Co., Ltd., Johnson & Johnson, Shin Nippon Biomedical Laboratories, Ltd., IBM Japan, Ltd., Code F (Financial Support), Renatech Co., Ltd., InnoJin Inc., Code P (Patent)